2.3(top 20%)
impact factor
5.1K(top 5%)
papers
79.6K(top 5%)
citations
87(top 5%)
h-index
2.3(top 20%)
extended IF
6.6K
all documents
84.8K
doc citations
129(top 10%)
g-index

Top Articles

#TitleJournalYearCitations
1Nanoparticles for drug delivery in cancer treatmentUrologic Oncology: Seminars and Original Investigations2008635
2A robust methodology to study urine microRNA as tumor marker: microRNA-126 and microRNA-182 are related to urinary bladder cancerUrologic Oncology: Seminars and Original Investigations2010579
3Micro-RNA profiling in kidney and bladder cancersUrologic Oncology: Seminars and Original Investigations2007569
4Expression of prostate-specific membrane antigen in normal, benign, and malignant prostate tissuesUrologic Oncology: Seminars and Original Investigations1995479
5Commentary on “Integrative clinical genomics of advanced prostate cancer” . Robinson D, Van Allen EM, Wu YM, Schultz N, Lonigro RJ, Mosquera JM, Montgomery B, Taplin ME, Pritchard CC, Attard G, Beltran H, Abida W, Bradley RK, Vinson J, Cao X, Vats P, Kunju LP, Hussain M, Feng FY, Tomlins SA, Cooney KA, Smith DC, Brennan C, Siddiqui J, Mehra R, Chen Y, Rathkopf DE, Morris MJ, Solomon SB, Durack JC, Reuter VE, Gopalan A, Gao J, Loda M, Lis RT, Bowden M, Balk SP, Gaviola G, Sougnez C, Gupta M, Yu EY, MostaghelUrologic Oncology: Seminars and Original Investigations2017307
6New frontiers in nanotechnology for cancer treatmentUrologic Oncology: Seminars and Original Investigations2008277
7Incidence trends in primary malignant penile cancerUrologic Oncology: Seminars and Original Investigations2007264
8Naturally-occurring canine transitional cell carcinoma of the urinary bladder A relevant model of human invasive bladder cancerUrologic Oncology: Seminars and Original Investigations2000246
9Molecular pathways of urothelial development and bladder tumorigenesisUrologic Oncology: Seminars and Original Investigations2010230
10Prospective analysis of sensitivity and specificity of urinary cytology and other urinary biomarkers for bladder cancerUrologic Oncology: Seminars and Original Investigations2015224
11Final results from a national multicenter phase II trial of combination bacillus Calmette-Guérin plus interferon α-2B for reducing recurrence of superficial bladder cancer☆Urologic Oncology: Seminars and Original Investigations2006222
12UroVysion FISH test for detecting urothelial cancers: Meta-analysis of diagnostic accuracy and comparison with urinary cytology testingUrologic Oncology: Seminars and Original Investigations2008221
13The impact of variant histology on the outcome of bladder cancer treated with curative intentUrologic Oncology: Seminars and Original Investigations2009212
14Clinical application of a 3D ultrasound-guided prostate biopsy systemUrologic Oncology: Seminars and Original Investigations2011207
15Multiparametric magnetic resonance imaging vs. standard care in men being evaluated for prostate cancer: A randomized studyUrologic Oncology: Seminars and Original Investigations2015197
16Molecular genetics of bladder cancer: Emerging mechanisms of tumor initiation and progressionUrologic Oncology: Seminars and Original Investigations2010191
17Combining urinary detection of TMPRSS2:ERG and PCA3 with serum PSA to predict diagnosis of prostate cancerUrologic Oncology: Seminars and Original Investigations2013183
18Mechanisms mediating androgen receptor reactivation after castrationUrologic Oncology: Seminars and Original Investigations2009181
19Bladder cancer in the elderlyUrologic Oncology: Seminars and Original Investigations2009179
20The prostate cancer-up-regulated long noncoding RNA PlncRNA-1 modulates apoptosis and proliferation through reciprocal regulation of androgen receptorUrologic Oncology: Seminars and Original Investigations2013177
21The “male lumpectomy”: Focal therapy for prostate cancer using cryoablation results in 48 patients with at least 2-year follow-upUrologic Oncology: Seminars and Original Investigations2008171
22Chronic inflammation and bladder cancerUrologic Oncology: Seminars and Original Investigations2007165
23Mode of presentation of renal cell carcinoma provides prognostic informationUrologic Oncology: Seminars and Original Investigations2002158
24Bladder cancer or bladder cancers? Genetically distinct malignant conditions of the urotheliumUrologic Oncology: Seminars and Original Investigations2010158
25KRN951, a highly potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, has antitumor activities and affects functional vascular propertiesUrologic Oncology: Seminars and Original Investigations2007156
26An open label, single-arm, phase II multicenter study of the safety and efficacy of CG0070 oncolytic vector regimen in patients with BCG-unresponsive non–muscle-invasive bladder cancer: Interim resultsUrologic Oncology: Seminars and Original Investigations2018155
27Gender, racial and age differences in bladder cancer incidence and mortalityUrologic Oncology: Seminars and Original Investigations2004152
28Transperineal 3D mapping biopsy of the prostate: An essential tool in selecting patients for focal prostate cancer therapyUrologic Oncology: Seminars and Original Investigations2008152
29ERK(MAPK) activity as a determinant of tumor growth and dormancy; regulation by p38(SAPK)Urologic Oncology: Seminars and Original Investigations2004151
30Granulocyte-macrophage colony-stimulating factor−transduced allogeneic cancer cellular immunotherapy: The GVAX® vaccine for prostate cancerUrologic Oncology: Seminars and Original Investigations2006146
31Commentary on “AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer.” Antonarakis ES, Lu C, Wang H, Luber B, Nakazawa M, Roeser JC, Chen Y, Mohammad TA, Chen Y, Fedor HL, Lotan TL, Zheng Q, De Marzo AM, Isaacs JT, Isaacs WB, Nadal R, Paller CJ, Denmeade SR, Carducci MA, Eisenberger MA, Luo J, Division of Urologic Oncology, Department of Urology, University of Michigan, MI. N Engl J Med 2014; 371(11):1028-38.Urologic Oncology: Seminars and Original Investigations2016145
32The prostate-specific membrane antigen: Lessons and current clinical implications from 20 years of researchUrologic Oncology: Seminars and Original Investigations2014143
33Phase II trial of oral 1,25-dihydroxyvitamin D (calcitriol) in hormone refractory prostate cancerUrologic Oncology: Seminars and Original Investigations1995142
34Variant (divergent) histologic differentiation in urothelial carcinoma is under-recognized in community practice: Impact of mandatory central pathology review at a large referral hospitalUrologic Oncology: Seminars and Original Investigations2013141
35SELECT: the selenium and vitamin E cancer prevention trialUrologic Oncology: Seminars and Original Investigations2003139
36Patterns of use of systemic chemotherapy for Medicare beneficiaries with urothelial bladder cancerUrologic Oncology: Seminars and Original Investigations2011138
37Bladder recurrence after surgery for upper urinary tract urothelial cell carcinoma: Frequency, risk factors, and surveillanceUrologic Oncology: Seminars and Original Investigations2011135
38Use of serial multiparametric magnetic resonance imaging in the management of patients with prostate cancer on active surveillanceUrologic Oncology: Seminars and Original Investigations2015135
39A prospective clinical trial of green tea for hormone refractory prostate cancer: An evaluation of the complementary/alternative therapy approachUrologic Oncology: Seminars and Original Investigations2005133
40Decreased NKX3.1 protein expression in focal prostatic atrophy, prostatic intraepithelial neoplasia, and adenocarcinoma: Association with Gleason score and chromosome 8p deletionUrologic Oncology: Seminars and Original Investigations2008130
41Natural history of untreated renal cell carcinoma with venous tumor thrombusUrologic Oncology: Seminars and Original Investigations2013129
42Clinical, prognostic, and therapeutic aspects of urachal carcinoma—A comprehensive review with meta-analysis of 1,010 casesUrologic Oncology: Seminars and Original Investigations2016128
43Permanent flank bulge is a consequence of flank incision for radical nephrectomy in one half of patientsUrologic Oncology: Seminars and Original Investigations2004127
44Randomized intergroup comparison of bacillus calmette-guerin immunotherapy and mitomycin C chemotherapy prophylaxis in superficial transitional cell carcinoma of the bladder a southwest oncology group studyUrologic Oncology: Seminars and Original Investigations1995125
45Sex-specific hormone receptors in urothelial carcinomas of the human urinary bladder: A comparative analysis of clinicopathological features and survival outcomes according to receptor expressionUrologic Oncology: Seminars and Original Investigations2011122
46A systematic review and meta-analysis on the oncological long-term outcomes after trimodality therapy and radical cystectomy with or without neoadjuvant chemotherapy for muscle-invasive bladder cancerUrologic Oncology: Seminars and Original Investigations2018122
47Urinary biomarkers in bladder cancer: A review of the current landscape and future directionsUrologic Oncology: Seminars and Original Investigations2021122
48Intravesical valrubicin in patients with bladder carcinoma in situ and contraindication to or failure after bacillus Calmette-GuérinUrologic Oncology: Seminars and Original Investigations2013121
49Statistical consideration for clinical biomarker research in bladder cancerUrologic Oncology: Seminars and Original Investigations2010120
50Commentary on “Abiraterone in metastatic prostate cancer without previous chemotherapy.” Ryan CJ, Smith MR, de Bono JS, Molina A, Logothetis CJ, de Souza P, Fizazi K, Mainwaring P, Piulats JM, Ng S, Carles J, Mulders PF, Basch E, Small EJ, Saad F, Schrijvers D, Van Poppel H, Mukherjee SD, Suttmann H, Gerritsen WR, Flaig TW, George DJ, Yu EY, Efstathiou E, Pantuck A, Winquist E, Higano CS, Taplin ME, Park Y, Kheoh T, Griffin T, Scher HI, Rathkopf DE; COU-AA-302 Investigators, Genitourinary Medical Oncology PUrologic Oncology: Seminars and Original Investigations2013113